Business
Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025
SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, is pleased to invite investors to a webinar on November 19, 2025, at 1:15 p.m. PT. The exclusive event, hosted by RedChip Companies, will feature Calidi’s CEO, Eric Poma, Ph.D. Attendees will gain insights into
About this update from Calidi Biotherapeutics, Inc.
[{"type":"image","alt":"Calidi Biotherapeutics, Inc","displaySize":"","headline":null,"caption":"Calidi Biotherapeutics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TVVsA9n31LT1YQqkVdlDAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8983e19176ab43568fb63e4ece5ad7a1","width":300,"height":93}},"lazy":false},{"type":"text","content":"SAN DIEGO, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, is pleased to invite investors to a webinar on November 19, 2025, at 1:15 p.m. PT.","length":371,"tagName":"p"},{"type":"text","content":"The exclusive event, hosted by RedChip Companies, will feature Calidi’s CEO, Eric Poma, Ph.D. Attendees will gain insights into Calidi’s pioneering approach to precision genetic medicine, enabled by its RedTail platform—an engineered, systemically delivered viral therapy designed to avoid immune detection and reach metastatic sites in the tumors Once at the tumor, the platform expresses potent genetic medicines, such as IL-15 superagonist, to drive an anti-tumor immune response.","length":483,"tagName":"p"},{"type":"text","content":"Preclinical data showcased at the Society of Immunotherapy for Cancer (SITC) annual conference demonstrated that in syngeneic murine models, the RedTail platform is protected from immune clearance after systemic administration and can find and specifically replicate in tumor cells at metastatic sites. The data also demonstrate that the platform can effectively express genetic medicines at the tumor site in concentrations that are similar to what is achievable with localized dosing while avoiding systemic exposure. With its scalable, non-integrating viral backbone and ability to deliver multiple genetic payloads, RedTail will position Calidi to penetrate a vast oncology market projected to exceed $560 billion by 2033 by Spherical Insights research. The Company is advancing toward IND filing by the end of 2026. Calidi’s third quarter 2025 earnings re...